Article

Economic Return of Clinical Trials Performed Under the Pediatric Exclusivity Program

Department of Pediatrics, Duke Clinical Research Institute, Duke University, Durham, NC 27705, USA.
JAMA The Journal of the American Medical Association (Impact Factor: 30.39). 03/2007; 297(5):480-8. DOI: 10.1001/jama.297.5.480
Source: PubMed

ABSTRACT In 1997, Congress authorized the US Food and Drug Administration (FDA) to grant 6-month extensions of marketing rights through the Pediatric Exclusivity Program if industry sponsors complete FDA-requested pediatric trials. The program has been praised for creating incentives for studies in children and has been criticized as a "windfall" to the innovator drug industry. This critique has been a substantial part of congressional debate on the program, which is due to expire in 2007.
To quantify the economic return to industry for completing pediatric exclusivity trials.
A cohort study of programs conducted for pediatric exclusivity. Nine drugs that were granted pediatric exclusivity were selected. From the final study reports submitted to the FDA (2002-2004), key elements of the clinical trial design and study operations were obtained, and the cost of performing each study was estimated and converted into estimates of after-tax cash outflows. Three-year market sales were obtained and converted into estimates of after-tax cash inflows based on 6 months of additional market protection. Net economic return (cash inflows minus outflows) and net return-to-costs ratio (net economic return divided by cash outflows) for each product were then calculated.
Net economic return and net return-to-cost ratio.
The indications studied reflect a broad representation of the program: asthma, tumors, attention-deficit/hyperactivity disorder, hypertension, depression/generalized anxiety disorder, diabetes mellitus, gastroesophageal reflux, bacterial infection, and bone mineralization. The distribution of net economic return for 6 months of exclusivity varied substantially among products (net economic return ranged from -$8.9 million to $507.9 million and net return-to-cost ratio ranged from -0.68 to 73.63).
The economic return for pediatric exclusivity is variable. As an incentive to complete much-needed clinical trials in children, pediatric exclusivity can generate lucrative returns or produce more modest returns on investment.

Download full-text

Full-text

Available from: Eric Eisenstein, Aug 12, 2015
0 Followers
 · 
138 Views
  • Source
    • "Components—Economic models are frequently used to evaluate problems for which it is not feasible to collect empirical data and have previously been used in studies of clinical research methods and practices [3] [6] [7] [8]. We developed three clinical research network economic models to estimate the data management costs for conducting clinical research studies using one centralized and two decentralized EDC data management strategies, as described above. "
    [Show abstract] [Hide abstract]
    ABSTRACT: New data management models are emerging in multi-center clinical studies. We evaluated the incremental costs associated with decentralized vs. centralized models. We developed clinical research network economic models to evaluate three data management models: centralized, decentralized with local software, and decentralized with shared database. Descriptive information from three clinical research studies served as inputs for these models. The primary outcome was total data management costs. Secondary outcomes included: data management costs for sites, local data centers, and central coordinating centers. Both decentralized models were more costly than the centralized model for each clinical research study: the decentralized with local software model was the most expensive. Decreasing the number of local data centers and case book pages reduced cost differentials between models. Decentralized vs. centralized data management in multi-center clinical research studies is associated with increases in data management costs.
    Studies in health technology and informatics 01/2011; 164:82-8. DOI:10.3233/978-1-60750-709-3-82
  • Source
    • "22 " Across diagnoses, cognitive capacity, physical functioning, and a diagnosis of mental illness have the greatest impact on decision-making capacity, with level of education also having an impact. " (Candilis et al. 2007). 23 DC Marson, a leading author in the special field, added " an enormous intergenerational transfer of wealth " as a reason of " the greatly expanded incidence and importance of capacity assessment of older adults " , e.g. for questioning the capacity to make a valid last will ( " Testierfähigkeit " ) (Moye and Marson 2007a). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Research in vulnerable populations, especially in minors and in the mentally ill, is becoming an increasing and urgent problem. For example, a large part of phar- maceuticals which is given to minors and adolescents is not licensed for them; whereas in other cases effective pharmaceuticals have not been developed yet (e.g. dementia). Recently, politicians have taken steps to remedy this deplorable state – e.g. by introducing the regulation (EC) No 1901/2006 on medicinal products for paediatric use. The realisation of this regulation, however, is causing a number of ethical, legal and economical problems: It is debated, to begin with, to what extent and on which ethical and legal foundation risky research in vulnerable popula- tions is acceptable at all. In addition, the realisation of clinical studies in smaller groups of patients (infants, minors, adolescents) is complex, time-consuming, and therefore very costly. Thus, the question arises whether the established ways of drug development are appropriate at all for fulfilling societal needs. The present volume is based on the talks given by an international panel of experts covering the fields of paediatrics, psychiatry, pharmacology, ethics, and law dur- ing the conference “Clinical Research in Vulnerable Populations” jointly organ- ised by the Berlin-Brandenburgische Akademie der Wissenschaften, the Klinik für Kinder- und Jugendpsychiatrie/Psychotherapie Universitätsklinikum Ulm and the Europäische Akademie GmbH in Berlin in April 2008.
    1 edited by Felix Thiele; Jörg M Fegert; Günter Stock, 01/2008; Europäische Akademie.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Historically, systemic hypertension was felt to occur in 1–4% of children (1–5); however, the prevalence is now increasing because of the influence of childhood obesity (6,7). Over the past three decades, childhood obesity has increased dramatically and has been deemed an epidemic by the Centers for Disease Control and Prevention (8). The 2002 National Health and Nutrition Examination Survey reported that the prevalence of overweight and obese children aged 6–19 years was 31%, a 45% increase from the previous survey (9). Not only is the prevalence of pediatric hypertension increasing, but also the condition is frequently underdiagnosed (10,11). In younger children, hypertension is often secondary to an underlying disorder while primary (or essential) hypertension accounts for up to 95% of cases in adolescents (12,13). Hypertension in this age group is linked to obesity and risk factors associated with metabolic syndrome that can lead to cardiovascular disease in later life, including lipid abnormalities and insulin resistance. Obesity has been linked to comorbid conditions in children, including type 2 diabetes mellitus, hypertension, and hyperlipidemia (14,15).
Show more